Three weeks in, the scale stops being the signal. The bloodwork is. By the time you pull labs at the Week 4 checkpoint, your body has already filed itself into one of three lanes — and the protocol that worked to get you here is not the protocol that gets you out. Practitioner consensus on cutting-phase peptide work converges on this: stack the same compounds for ten weeks regardless of response, and you either plateau, crash the thyroid, or rebound on appetite the second you taper. The lab panel sorts you. The next stack is determined by which lane you're in.
What the labs are actually measuring
The cellular question underneath every cutting-phase lab is whether the body is burning fat or down-regulating to survive. Those produce nearly identical scale numbers and wildly different compositional outcomes. The deficit triggers a defensive cascade: sympathetic tone climbs, cortisol stays elevated, thyroid output drops, and the liver converts more T4 into reverse T3 — which docks at the T3 receptor but produces no metabolic signal. The mitochondria literally shrink. At that point the scale may still move from glycogen depletion and water loss, but lean mass is bleeding and fat oxidation has stalled.
The cutting-phase peptide stack — GLP-1 / GIP / glucagon agonism for appetite and substrate partitioning, MOTS-c for mitochondrial fat oxidation, the GH-axis layer for lean preservation — interrupts that cascade at three different points. A clear responder shows interruption succeeding across all three. A partial responder shows one or two pathways working and one failing. A non-responder shows the defensive cascade winning anyway, usually because the deficit was too aggressive, the appetite layer was over-dosed, or the metabolic floor (fasting insulin, fT3, IGF-1) was wrong before the protocol started.
The Week 4 lab panel — fasting insulin, fT3, reverse T3, IGF-1, DHEA-S, and a measured (not estimated) body composition delta — tells you which.
Lane 1 — Clear responder
You're here if: fT3 has held within 15% of baseline, reverse T3 is flat, fasting insulin is dropping toward the optimal range, body composition shift is visible at the same scale weight, and appetite suppression is steady but not excessive. The substrate's framing is direct: find the minimum dose that keeps fat loss moving and don't push past it. Aggressive titration from this position is the most common way clear responders convert themselves into non-responders by Week 8.
| Compound | Dose | Route | Frequency | Evidence Tier | Notes |
|---|---|---|---|---|---|
| Retatrutide | Hold at current dose (typical 0.5 mg by Week 5 per practitioner protocols) | SubQ | Weekly | 🟢 Expert | Substrate: dial back if appetite suppression becomes "excessive" — find the minimum that maintains trajectory |
| MOTS-c | Maintain current dosing | SubQ | Per existing schedule | 🟣 Experimental | Practitioner consensus: keep the mitochondrial fat-oxidation layer running — this is the compound making the fat actually burn |
| GH-axis support (CJC-1295 no-DAC / Ipamorelin) | Maintain | SubQ | Pre-sleep | 🟢 Expert | Only if fasting insulin held below 8 mIU/L — substrate is explicit that GH secretagogues are contraindicated above this threshold |
| Refeed | Carb-forward day every 14-21 days | Oral | As scheduled | 🟢 Expert | Substrate: refeed at least once every 4 weeks at maximum 1000 cal/day deficit prevents the thyroid drop |
Lane 1 rule: don't add compounds. The protocol is working. Increasing the dose, layering a new compound, or extending the deficit window all push toward Lane 3.
Lane 2 — Partial responder
You're here if one signal is moving and another is not. The two common patterns: scale moving, composition stalled (appetite suppression is doing its job but fat oxidation isn't keeping pace — you're losing lean mass), or composition shifting, scale stuck (water and glycogen rebound is masking real fat loss). fT3 is usually softened but not crashed. Fasting insulin may be flat instead of dropping. Reverse T3 trends up but hasn't peaked.
The intervention is mechanism-specific. If the scale is moving but composition isn't, the deficit is too aggressive and the GLP-1 layer is doing all the work — you're catabolizing. If composition is shifting but scale is stuck, the fat-oxidation pathway needs reinforcement and the deficit may need a brief refeed window.
| Compound | Dose | Route | Frequency | Evidence Tier | Notes |
|---|---|---|---|---|---|
| Retatrutide | Reduce by 25-50% if appetite suppression excessive | SubQ | Weekly | 🟢 Expert | Substrate: excessive appetite suppression drives lean loss and post-protocol rebound |
| MOTS-c | Increase frequency within practitioner range | SubQ | More frequent dosing | 🟣 Experimental | Substrate-anchored: MOTS-c is the lever that makes mobilized fat actually oxidize — under-dosed here is the common failure |
| Tesamorelin (add if VAT is the stalled metric) | Standard practitioner range | SubQ | Daily | 🔵 Clinical | Substrate: the only GH secretagogue with full FDA approval and robust clinical trial data for visceral fat. Add only if visceral fat is the stalled compartment |
| Refeed | Insert 3-7 day flexible-eating window | Oral | Single window | 🟢 Expert | Substrate: refeed of 1-7 days every 4 weeks prevents thyroid down-regulation; pull it forward when fT3 softens |
| Lean-mass insurance (GH-axis or IGF-1 short-acting) | [practitioner corpus thin on cutting-phase IGF-1 LR3 — track and report] | — | — | — | Substrate covers IGF-1 in growth/recovery context but is sparse on cutting-phase deployment specifics |
Lane 2 rule: one variable changes per two-week block. Adjusting three things at once destroys the signal.
Lane 3 — Non-responder
You're here if fT3 has dropped more than 20% from baseline, reverse T3 is climbing, fasting insulin hasn't moved or has worsened, IGF-1 has dropped below 150, body composition is flat or regressing, and fatigue is dominant. This is the defensive cascade winning. The thyroid is throttling the metabolism, cortisol is elevated, and the deficit is no longer producing fat loss — it's producing adaptation.
Practitioner consensus on this state is unanimous: do not push the existing stack harder. Adding more GLP-1, adding more MOTS-c, layering a new compound — none of these address the actual problem, which is that the body has decided survival matters more than the deficit. The intervention is metabolic rescue first, protocol restart second.
| Phase | Intervention | Duration | Evidence Tier | Notes |
|---|---|---|---|---|
| Stop the cut | Move to maintenance calories | 7-14 days | 🟢 Expert | Substrate: thyroid recovery requires the deficit signal to lift before fT3 will climb |
| Hold GLP-1 / GIP / glucagon agonist | Continue at reduced dose | Through rescue window | 🟢 Expert | Discontinuing abruptly drives rebound hyperphagia — substrate frames this as the dominant compulsive-eating risk |
| Discontinue GH secretagogues if fasting insulin > 8 mIU/L | Stop until insulin corrects | Until fasting insulin normalizes | 🟢 Expert | Substrate is explicit: GH antagonizes insulin — running GH-axis support on top of insulin resistance worsens both |
| Carb-forward refeed | 3-7 consecutive days | One window | 🟢 Expert | Substrate: maximum 1000 cal/day deficit with refeed once every 4 weeks is the protective range; non-responders need a longer refeed window |
| Re-pull labs | fT3, reverse T3, fasting insulin, IGF-1, DHEA-S | Week 6 of rescue | — | Restart protocol decisions get made off the recovered panel, not the crashed one |
After the rescue window, the lane assignment runs again. Most non-responders return as Lane 2 partial responders on the restart, with a smaller deficit and a slower titration.
What's NOT happening yet
- The Week 4 panel is not your final verdict. The lane can shift by Week 6. Re-pull.
- A non-responder lab pattern is not a personal failure. Substrate consensus: it's a signal that the deficit aggression, the appetite-layer dose, or the starting metabolic floor was wrong — not that the compounds don't work.
- Adding compounds is not the answer for non-responders. The defensive cascade doesn't get out-stacked. It gets interrupted by lifting the deficit signal.
- Scale movement is not composition movement. A clear responder and a non-responder can show identical scale deltas at Week 4 — the lab panel is what separates them.
- The Lane 1 protocol is not better than the Lane 3 protocol. They're answers to different questions. Running Lane 1 instructions in a Lane 3 body is how the rest of the protocol fails.
Research describes these lanes. Pull the labs. Sort yourself. Adjust.